<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03559621</url>
  </required_header>
  <id_info>
    <org_study_id>the Melinda study</org_study_id>
    <nct_id>NCT03559621</nct_id>
  </id_info>
  <brief_title>Mobile-based Lifestyle Intervention in Women With Glucose Intolerance After Gestational Diabetes</brief_title>
  <acronym>MELINDA</acronym>
  <official_title>Mobile-based Lifestyle Intervention in Women With Glucose Intolerance After Gestational Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although lifestyle modification programs have been shown to be effective in preventing
      diabetes in older populations, interventions in women with recent gestational diabetes (GDM)
      clearly need to be adapted to address their unique barriers to behavior change in order to
      optimize adherence. The low participating rates in many studies using individual or group
      sessions, reflect how difficult it is to engage women in the first years postpartum. Since
      women with glucose intolerance (prediabetes) have the highest risk to develop type 2 diabetes
      (T2DM), we designed the MELINDA pilot study, a randomized controlled trial with 1 year of
      follow-up to evaluate the efficacy and feasibility of a telephone -and mobile (app) based
      lifestyle coaching intervention in women with glucose intolerance after a recent history of
      GDM to promote a healthy lifestyle.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 6, 2019</start_date>
  <completion_date type="Anticipated">June 6, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 6, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>RCT with a mobile based lifestyle intervention</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>weight-loss goal</measure>
    <time_frame>1 year</time_frame>
    <description>reaching the weight-loss goal â‰¥5% of body weight when overweight or obese or returning to pre-gravid weight if normal BMI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>diabetes</measure>
    <time_frame>1 year</time_frame>
    <description>development of type 2 diabetes based on the ADA criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prediabetes</measure>
    <time_frame>6-16 weeks postpartum</time_frame>
    <description>prevalence of prediabetes based on the ADA criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prediabetes</measure>
    <time_frame>1 year postpartum</time_frame>
    <description>prevalence of prediabetes based on the ADA criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic syndrome</measure>
    <time_frame>1 year</time_frame>
    <description>development of a metabolic syndrome based on the WHO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic syndrome</measure>
    <time_frame>6-16 weeks postpartum</time_frame>
    <description>development of a metabolic syndrome based on the WHO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin resistance Matsuda</measure>
    <time_frame>1 year</time_frame>
    <description>insulin resistance measured by Matsuda index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin resistance HOMA-IR</measure>
    <time_frame>1 year</time_frame>
    <description>insulin resistance measured by HOMA-IR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>beta-cell function ISSI-2 index</measure>
    <time_frame>1 year</time_frame>
    <description>beta-cell function measured by ISSI-2 index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>beta-cell function insulinogenic index</measure>
    <time_frame>1 year</time_frame>
    <description>beta-cell function measured by insulinogenic index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>beta-cell function HOMA-B</measure>
    <time_frame>1 year</time_frame>
    <description>beta-cell function measured by HOMA-B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight loss</measure>
    <time_frame>1 year</time_frame>
    <description>mean weight loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration breastfeeding</measure>
    <time_frame>1 year</time_frame>
    <description>self-designed questionnaire to evaluate duration of breastfeeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate exclusive breastfeeding</measure>
    <time_frame>1 year</time_frame>
    <description>self-designed questionnaire to evaluate rate of exclusive breastfeeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>depression</measure>
    <time_frame>1 year</time_frame>
    <description>CES-D questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anxiety</measure>
    <time_frame>1 year</time_frame>
    <description>STAI-6 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>motivation for behavior change</measure>
    <time_frame>1 year</time_frame>
    <description>the TSRQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dietary quality</measure>
    <time_frame>1 year</time_frame>
    <description>Flemish FFQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical activity IPAQ</measure>
    <time_frame>1 year</time_frame>
    <description>IPAQ questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical activity pedometer</measure>
    <time_frame>1 year</time_frame>
    <description>pedometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diabetes risk perception</measure>
    <time_frame>1 year</time_frame>
    <description>diabetes risk perception questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sence of Coherence</measure>
    <time_frame>1 year</time_frame>
    <description>Sence of Coherence (SOC) questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Gestational Diabetes</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Glucose Intolerance</condition>
  <condition>Healthy Lifestyle</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Women in the control group will receive follow-up as in normal routine with referral to primary care. They will receive an OGTT after 1 year as part of the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A mobile-based lifestyle intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>mobile-based lifestyle intervention</intervention_name>
    <description>one face-to-face coaching within 2 weeks after randomization, monthly telephonic coaching -and continuous use of the app as needed</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 18 or older

          -  GDM based on the 2013 WHO criteria

          -  glucose intolerance (prediabetes based on the ADA criteria) based on the 75g OGTT 6-16
             weeks after delivery

        Exclusion Criteria:

          -  diabetes;

          -  current use of metformin;

          -  normal glucose tolerance (ADA criteria);

          -  health limitations or treatments which would restrict the participation in the
             intervention trial.

          -  Has no smartphone
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katrien Benhalima, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katrien Benhalima, MD PhD</last_name>
    <phone>16340614</phone>
    <phone_ext>032</phone_ext>
    <email>katrien.benhalima@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>OLV Aalst-Asse</name>
      <address>
        <city>Aalst</city>
        <state>Oost-Vlaanderen</state>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Inge Van Pottelbergh, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GZA</name>
      <address>
        <city>Antwerpen</city>
        <zip>2018</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Pascale Abrams, MD</last_name>
    </contact>
    <investigator>
      <last_name>Wouter Vink, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZA</name>
      <address>
        <city>Antwerpen</city>
        <zip>2560</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Bonheiden</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Toon Maes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Liesbeth Leuridan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Nancy Van Wilder, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge Kortrijk</name>
      <address>
        <city>Kortrijk</city>
        <zip>8510</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Nele Myngheer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>November 19, 2018</last_update_submitted>
  <last_update_submitted_qc>November 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

